OncoPro Dx

RAPIDLY IDENTIFY CLINICALLY SIGNIFICANT GENE MUTATIONS ACROSS MULTIPLE FORMS OF CANCER

Oncology Diagnostics

Turnaround time (TAT) and accuracy of molecular diagnostic test results are two of the most critical elements of cancer patient care, especially for lung, colon, breast, and melanoma cancers. Integrity Laboratories has tested thousands of genetic mutations using formalin-fixed paraffin-embedded (FFPE) tissue specimens through our LDTs and is the only local laboratory in this area that provides:
  • Ability to formualte first line treatment strategies in days, not weeks.
  • Unsurpassed Technology via PCR + Mass Spectrometry (MALDI-TOF)
  • Complete on-site testing and reporting
  • 100% Sensitivity & 99% Specificity
  • Small Sample Size
    • o 3-5 scrolls FFPE specimen
    • o 100 DNA/RNA
    • o A/RNA
    • o 10% neoplastic cells

OncoPro Dx Test Menu

OncoPro Dx Lung

OncoPro Dx Lung test detects 127 clinically relevant variants across 5 oncogenes–BRAF,EGFR, ERBB2, KRAS, and PIK3CA for comprehensive profiling of lung cancer. This rapid approach can allow oncologists to quickly identify the most appropriate molecular targeted therapy for their patients with lung cancer.

OncoPro Dx Lung NSCLC

OncoPro Dx Lung NSCLC test precisely detects 192 clinically relevant variants across 10oncogenes–ALK, BRAF, EGFR, ERBB2, KRAS, MET, NTRK1, PIKC3CA, RET, ROS1 for comprehensive profiling of lung NSCLC cancer in FFPE tissue. This rapid approach can allow oncologists to quickly identify mutations in NSCLC and assist with personalized treatment.

OncoPro Dx Colon

OncoPro Dx Colon test precisely detects 124 actionable mutations in 5 genes–BRAF, EGFR,KRAS, NRAS, PIK3CA in FFPE tissue. This rapid approach can allow oncologists to quickly identify mutations and assist with the most appropriate molecular targeted therapy for their patients diagnosed with colon cancer.

OncoPro Dx Melanoma

OncoPro Dx Melanoma test precisely detects 97 actionable mutations in 11 genes-BRAF,GNA11, GNAQ, HRAS, KIT, KRAS, NRAS, PTEN, RAC1, RPS27, and TERT in FFPE tissue. This rapid approach can allow oncologists to quickly identify mutations and assist with the most appropriate targeted therapy for their patients diagnosed with melanoma.

OncoPro Dx Fusion

OncoPro Dx Fusion test precisely detects 65 mutations (fusion, rearrangements, or skipping) in 5 genes–ALK, MET, NTRK1, RET, and ROS1 in FFPE tissue. This rapid approach can allow oncologists to quickly identify mutations and assist with the most appropriate targeted therapy for their cancer patients.

OncoPro Dx EGFR

OncoPro Dx EGFR test precisely detects 6 mutations in EGFR gene in FFPE tissue. This rapid approach can allow oncologists to quickly identify mutations and monitor the responses to TKI-targeted therapies in patients.

OncoPro Dx PIK3CA

OncoPro Dx PIK3CA testprecisely detects 20 mutations in PIK3CA gene in FFPE tissue. Thisrapid approach can allow oncologists to quickly identify mutations and assist with the mostappropriate molecular targeted therapy for their patients diagnosed with breast cancer.

RAPIDLY IDENTIFY CLINICALLY SIGNIFICANT GENE MUTATIONS FOR NSCLC LUNG CANCER

Integrity’s OncoPro Dx testing process Delivers Actionable Results Fast, Using State Of The Art Technologies To Identify Relevant Biomarkers That Support Clinicians in Delivering Personalized Cancer Therapies

Integrity Laboratories began testing for SARS-CoV-2 (COVID-19) under Emergency Use Authorization (EUA) on March 23.

Please direct all inquiries to covid19@integritylaboratories.com for immediate review.

Click Here for CDC recommendations for Identifying Monkeypox.

FDA Authorization Letter   |   FDA EUA Summary

CARES Act Statement